Mechanism of Coptisine in Rotator Cuff Injury: PI3K/Akt/mTORinflammation Crosstalk Uncovered by Network Pharmacology and Experimental Validation

Le résumé fourni par la source

INTRODUCTION: This study aimed to investigate the therapeutic mechanism of coptisine in rotator cuff injury (RCI) through network pharmacology and experimental validation. This is the first study to examine the role of coptisine in rotator cuff injury (RCI), revealing a novel mechanism by which coptisine inhibits the PI3K/Akt/mTOR pathway, thereby coordinating inflammation resolution and tendon repair. METHODS: Network pharmacology was used to identify potential coptisine and RCI targets, which were then analyzed functionally to indicate critical pathways. A rat RCI model (right supraspinatus tendon transection) was used to validate the mechanism by detecting pathological changes, inflammatory factors, and mRNA expression related to the PI3K/Akt/mTOR pathway. RESULTS: Network pharmacology identified 29 overlapping coptisine and RCI targets, with an emphasis on the PI3K/Akt/mTOR pathway. Coptisine reduced tendon atrophy and inflammation in RCI rats, lowered blood TNF-α and IL-6 levels, elevated IL-10, and decreased PI3K, Akt, and mTOR mRNA expression in tendon tissues. CONCLUSION: Coptisine improved RCI in rats by decreasing inflammation and the PI3K/Akt/ mTOR pathway, suggesting a possible therapeutic target for RCI.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.